NICE has terminated its appraisal of baloxavir marboxil (Xofluza) for the treatment and prevention of influenza in children aged 1 to 11 years. The appraisal was terminated because the pharmaceutical company did not submit the required evidence for review. This means no recommendation will be made for the use of this drug in this pediatric population under the technology appraisal process.

This termination means that healthcare providers and patients will not receive a NICE recommendation for baloxavir marboxil for this specific indication. Drug manufacturers seeking approval or recommendation for new treatments should ensure timely and complete evidence submissions to regulatory bodies like NICE. The decision may be revisited if the company decides to make a future submission.